MetaCap

BridgeBio Oncology Therapeutics Inc. (BBOT)

NASDAQ: BBOTHealth CareBiotechnology: Pharmaceutical PreparationsUSD

1.81-0.05 (-2.69%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

BBOT stock chart

Technical analysis

Key statistics

All statistics
Market cap
$145.25M
52-week range
1.79 – 14.87
Day range
1.79 – 1.94
Volume / Avg
450.96K / 631.56K
Beta
—

52-week range

$1.79$14.87

BBOT stock today

On Nov 20, BBOT ended the session at $1.81, shedding $0.05 (2.69%), versus the S&P 500's 3.70% decline. Shares are 87.8% below their 52-week high of $14.87, set on Dec 8, 2025 and 1.4% above the 52-week low of $1.79, near the bottom of the past year's range. BBOT is down 85.5% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 85.4%.

BridgeBio Oncology Therapeutics trades at 3.4x its trailing twelve-month earnings per share of $0.53.

Summary generated from market data by MetaCap's automated system. Methodology

About BridgeBio Oncology Therapeutics

Company profile

BridgeBio Oncology Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of small-molecule therapeutics for the treatment of renin-angiotensin system and phosphoinositide 3-kinase malignancies in the United States. The company develops BBO-8520, an orally bioavailable small molecule direct inhibitor, which is in Phase I clinical trial for the treatment of patients with KRASG12C mutant non-small cell lung cancer; and BBO-11818, an orally bioavailable small molecule pan-KRAS inhibitor, which is in Phase I clinical trial for the treatment of patients with KRAS G12D and KRAS G12V cell-derived xenograft models. It is also involved in the development of BBO-10203, an orally bioavailable small molecule, which is in Phase I clinical trial for the treatment of patients with HER2+ breast cancer, HR+/HER2- breast cancer, KRAS mutant colorectal cancer, and KRAS mutant non-small cell lung cancer; and precision oncology assets for patients with tumors.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Dr. Pedro J. Beltran M.D., Ph.D.
Headquarters
South San Francisco, CA
Employees
92
IPO year
2024
Website
bbotx.com

Financial highlights

Full financials

BridgeBio Oncology Therapeutics reported a net loss of $134.0 million, compared with a loss of $74.3 million a year earlier. Diluted earnings per share came in at -$4.30.

BridgeBio Oncology Therapeutics annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023
Revenue———
Growth———
Net income$-134.04M$-74.28M$-41.69K
EPS (diluted)$-4.30$-5,756.41—

Analyst forecast

Forecast

Consensus (12 analysts)

strong_buy

Avg. price target

$21.00+1060.22%

  • Strong buy 4
  • Buy 8
  • Hold 0
  • Sell 0
  • Strong sell 0

Target range

Low $9.00High $50.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 11, 2026
EPS actual vs est.
$-0.43 vs $-0.65
Surprise
+33.85%

BBOT news

All BBOT news

BridgeBio Oncology Therapeutics peers

Health Care sector
BBOT peer companies
CompanyPrice% ChgMarket capCompare
PRQRProQR Therapeutics N.V.1.04-0.95%$146.98Mvs BBOT
VRXAVeraxa Biotech AG1.04+0.97%$147.06Mvs BBOT
RNAAtrium Therapeutics Inc.6.92-0.86%$149.27Mvs BBOT
ELDNEledon Pharmaceuticals Inc.1.78-6.32%$150.34Mvs BBOT
IFRXInflaRx N.V.1.04-4.59%$153.26Mvs BBOT
ALXOALX Oncology Holdings Inc.1.06+3.92%$137.03Mvs BBOT
ORMPOramed Pharmaceuticals Inc.3.57-3.25%$155.24Mvs BBOT
ZNTLZentalis Pharmaceuticals Inc.1.360.00%$133.64Mvs BBOT

Indexes, lists and sector

BridgeBio Oncology Therapeutics stock FAQ

What is BridgeBio Oncology Therapeutics's stock price today?

BBOT last traded at $1.81 as of Nov 20, 4:00 PM EST, down 2.69% on the day. Prices are delayed at least 15 minutes.

What is BBOT's P/E ratio?

BBOT trades at a trailing P/E ratio of 3.42.

Who is BridgeBio Oncology Therapeutics's CEO?

Dr. Pedro J. Beltran M.D., Ph.D. is the chief executive officer of BridgeBio Oncology Therapeutics Inc., which has about 92 employees.

What is the BBOT 52-week high?

The 52-week high for BBOT is $14.87 and the 52-week low is $1.79. The stock is currently 87.8% below its high.

Compare BBOT